Introduction
Patients and methods
Infection of the vagina with Candida albicans is a common condition.1"3 Most women respond well to topical medication, although patient compliance can be a problem4 and relapse is common.5 Short-term therapy requiring the minimum of co-operation from the patient has advantages, and to this end imidazole analogues were developed as antifungal agents. Econazole nitrate (Gynopevaryl, Ortho Pharmaceutical Ltd, High Wycombe, Bucks) is a new broad-spectrum antimycotic agent, which has been shown to be effective against dermatophytes, yeasts, and Gram-positive bacteria6; reports of clinical studies of the treatment of vaginal candidosis have indicated cure rates of about 9307o.
Obtaining adequate follow-up data for studies of vaginal candidosis, particularly with patients seen at departments of genitourinary medicine, is always difficult. Poor attendance rates for follow-up visits can introduce an adverse bias in the calculation of cure rates, since the women whose conditions have been cured are less likely to return to the clinic than those whose problems persist. This Patients were allocated according to a random code to one of two treatment groups. One group (group 1) was given three econazole nitrate 150-mg pessaries and instructed to insert one pessary high into the vagina for three consecutive nights. The other group (group 2) was given 28 nystatin pessaries (100 000 units per tablet) with instructions to insert two pessaries into the vagina for 14 consecutive nights. Written directions for the use of the medication was given to each woman; these stressed the need for compliance and instructed patients to continue treatment regardless of menstruation.
FOLLOW-UP
The first follow-up visit took place one week after the end of treatment and subsequent visits at six and 12 weeks after enrolment. Patients were asked whether they had taken any additional medication or changed their existing medication, in particular hormonal oral contraceptives; if they had, they were excluded from the study.
At each follow-up visit the patient was questioned about her symptoms, and tests for C albicans and T vaginalis were repeated as already described.
STATISTICAL ANALYSIS
The x2 test with Yates's correction was used.
Results
Of the 224 patients enrolled into the study, 120 were given econazole nitrate (group 1) and 104 nystatin (group 2). Forty-three patients in group 2 and 35 in group 1 were subsequently excluded from the study, which left 146 records suitable for analysis. The reasons for exclusion are summarised in table I; the commonest was failure to return to the clinic for Vaginal discharge as a symptom persisted in 16% of group 2 and in 29% of group 1. This difference was not significant (X2-=2-63; 0 2>P>O 1) nor was the difference between groups for the incidence of pruritus (X2=0-71; 0N5>P>0 3). The fact that women from group 1 returned for follow-up 10 days after the start of therapy and those in group 2 three weeks after the start of therapy should also be considered when the results of the changes in symptoms are interpreted.
A rise in the percentage incidence of clinical signs and symptoms was recorded at the second compared with the first follow-up visit, probably because of the problems of the relapsed and reinfected patients.
The number of women who returned for their third follow-up visit was very small and few valid comments can be made on the findings.
PATIENTS' COMMENTS
Any comments made spontaneously by the women were recorded at each follow-up visit. Such anecdotal information is very difficult to summarise but could be roughly classed as adverse or favourable. For nystatin treatment three favourable comments were made, ranging in enthusiasm from "not unpleasant" to "helped a lot." Ten women complained that they J S Bingham and C E Steele were messy, three found them difficult to insert, and three objected to the length of treatment. Thirteen women treated with econazole nitrate made favourable comments, mainly about the ease of insertion, shortness of treatment, and efficacy of cure. Nine patients remarked that some soreness persisted after the completion of econazole nitrate therapy. However, this finding should again be considered in the light of the different timings in follow-up between the two treatment groups.
Discussion
If large numbers of patients default from a clinical study, the interpretation of results becomes very difficult. About 35% of the patients enrolled in this study failed to return for follow-up evaluation. However, the inclusion of a control group treated with standard nystatin therapy has allowed comment to be made on the relative efficacy of econazole nitrate.
Nystatin treatment, consisting of 200 000 units (two tablets) for 14 days showed no superiority over 15-mg pessaries of econazole nitrate treatment for three days in either cure rate or relief of signs and symptoms.
The problem of patient compliance has previously been mentioned and treatment completed within three days probably offers an advantage, since there is more chance that patients will successfully complete a short course of treatment. Comments on the acceptability of the two vaginal products highlights the importance of presentation. The nystatin pessary is a dry compressed tablet, which can cause discomfort when inserted into an inflamed vagina and, when dissolved, can produce leakage. About one-quarter of the patients treated with nystatin complained spontaneously about these problems. (1) 
